RxDoctor Payments Data

Cynthia McCumbers

Acute Care · Sidney, NENPI 1801860341

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 44.6% of the total.

$1,140in general payments, 2019–2025

Across 86 payments — averaging $13.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$509
  • Johnson & Johnson$132
  • Scpharmaceuticals Inc.$112
  • Novartis$94
  • Merck$81
  • Itamar Medical Inc$75
  • plus $136 from 4 others

What the payments were for

  • Food & beverage$1,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,140 in reported general payments places this provider in the 70th percentile of 103 acute care providers in Nebraska.

See all acute care providers in Nebraska

Medicare billing

Part B allowed, 2024
$66,190
Medicare patients
720
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$150,903
JardianceEmpagliflozin104$82,984
XareltoRivaroxaban52$54,564
EntrestoSacubitril/Valsartan31$30,403
FarxigaDapagliflozin Propanediol29$20,139
Metoprolol Succinate271$4,084
Bumetanide79$3,225
Atorvastatin Calcium198$1,543
Losartan Potassium143$1,197
Spironolactone219$1,104
Potassium Chloride66$856
Carvedilol155$827
Metoprolol Tartrate111$685
Valsartan30$679
Amiodarone Hcl41$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$150,903157 claims
Johnson & JohnsonXarelto$132$54,56452 claims
NovartisEntresto$94$30,40331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 103 acute care providers in Nebraska.

Other acute care in Sidney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →